Non-small cell lung cancer (NSCLC) is one of the most devestating diagnoses and highest unmet needs in the oncology space. EQRx, which intends to solve pricing and access challenges for patients, unveiled new data at the European Society for Medical Oncology (ESMO) Congress 2021 showing that it might just have the answer to NSCLC too.
If you are not happy with the results below please do another search
50 search results for:
Researchers at the University of Illinois at Chicago published what they are calling a “first of its kind study” that found a possible direct link between neurodegenerative diseases and the herpesvirus.
Vifor Pharma and Travere Therapeutics inked a collaboration and licensing partnership to commercialize sparsentan in Europe, Australia and New Zealand. The drug is being developed to treat FSGS and IgAN, which are rare progressive kidney diseases that are leading causes of end-stage kidney disease.
Although the U.S. Bankruptcy Court approved the OxyContin maker’s reorganization plan that freed the Sacklers from greater financial accountability and shielded them from additional lawsuits, the Department of Justice moved to block the Purdue Pharma bankruptcy deal.
Biopharma companies big and small presented exciting clinical studies at the European Society for Medical Oncology Congress 2021.
The Novo Nordisk Foundation is partnering with the Broad Institute of MIT and Harvard University to launch a massive genetic data mining project that aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
A third shot of Sinopharm’s Covid-19 vaccine leads to a rebound in antibody levels that drop months after a second dose, a small-scale Chinese study showed.
U.S. President Joe Biden on Sept. 16 directed his ire at the governors of Florida and Texas, accusing the Republican leaders of “doing everything they can to undermine the life-saving requirements” he proposed to counter the spread of Covid-19.
External advisors to the U.S. Food and Drug Administration will meet on Sept. 17 to consider data from Pfizer and BioNTech in support of booster shots. Meanwhile, a timeline is being presented on the authorization of Covid-19 vaccines for children.
The U.S. Food and Drug Administration said on Sept. 16 it has revised the FDA’s emergency use authorization for Eli Lilly’s Covid-19 antibody cocktail to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease.